Remote Ischemic Conditioning Combined With Endovascular Stenting for Symptomatic Intracranial Atherosclerotic Stenosis
Launched by TIANJIN HUANHU HOSPITAL · Dec 15, 2022
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment method called Remote Ischemic Conditioning (RIC) for patients who have a narrowing of the arteries in the brain, known as symptomatic intracranial atherosclerotic stenosis (sICAS). The goal is to see if combining RIC with an endovascular procedure—where doctors use a thin tube to treat the narrowed arteries—can improve safety and effectiveness for patients. The trial is currently not recruiting participants but aims to include adults aged 18 and older who have significant narrowing of their brain arteries and a history of strokes or mini-strokes caused by this condition.
To be eligible for this study, participants must be admitted to the hospital between January 1, 2023, and January 1, 2025, and have a specific level of artery narrowing confirmed by imaging tests. They also need to be able to provide consent for participation. However, individuals with certain health issues, such as high blood pressure that is not controlled or other causes of artery narrowing, will not be included. If you join this trial, you can expect to receive specialized care while contributing to important research that could help improve treatments for similar conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient admitted from Jan. 1st 2023 to Jan. 1st 2025;
- • 2. Age ≥ 18;
- • 3. Intracranial atherosclerosis stenosis measured as ≥70% by digital subtraction angiography or by other noninvasive methods, such as transcranial doppler, computed tomography angiography, or magnetic resonance angiography;
- • 4. A history of stroke/transient ischemic attack attributed to ICAS;
- • 5. Verbal and written informed consent is provided at the time of admission by patients or their legally authorized representatives.
- Exclusion Criteria:
- • 1. Stenosis of other causes;
- • 2. Prior ipsilateral stroke with residual deficits;
- • 3. Uncontrolled hypertension (defined as systolic blood pressure ≥200 mm Hg despite medications at enrollment);
- • 4. Peripheral vascular disease (especially subclavian arterial and upper limb artery stenosis or occlusion).
About Tianjin Huanhu Hospital
Tianjin Huanhu Hospital is a leading medical institution in Tianjin, China, dedicated to providing high-quality healthcare services and advancing medical research. As a clinical trial sponsor, the hospital is committed to fostering innovation in medical treatments and therapies through rigorous scientific investigation. With a multidisciplinary team of experienced healthcare professionals and researchers, Tianjin Huanhu Hospital adheres to the highest ethical standards and regulatory guidelines to ensure patient safety and data integrity. The hospital’s state-of-the-art facilities and collaborative approach facilitate the successful execution of clinical trials, contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, Tianjin, China
Patients applied
Trial Officials
Ming Wei, PhD
Principal Investigator
Tianjin Huanhu Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials